

11 June 2026

Cancer Treatments in Secondary Care

Please could you provide answers to the questions below regarding the number of patients treated with the specific medicines between the start of January 2026 to the end of March 2026, or for the most recent three-month period available? I would be grateful if the data provided could include all hospitals within the Health and Social Care Trust.

1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Avelumab (Bavencio)	<5
1.2 Atezolizumab (Tecentriq)	28
1.3 Pembrolizumab (Keytruda)	148
1.4 Nivolumab (Opdivo)	102
1.5 Durvalumab (Imfinzi)	32
1.6 Erdafitinib (Balversa)	0
1.7 Enfortumab vedotin (Padcev)	5
1.8 Cisplatin	84
1.9 Carboplatin	235
1.10 Gemcitabine	67

2. How many patients were treated with avelumab (Bavencio) for the following types of cancer in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Name of monotherapy or combination	Number patients treated
Merkel Cell Carcinoma (ICD-10 codes = C4A* and/or morphology code = 8247/3)	<5

11 June 2026

Urothelial Carcinoma (ICD-10 codes = C65*, C66*, C67* and/or morphology code = 8120*, 8130*, 8131/3, 8122/3, 8031/3)	0
Renal Cell Carcinoma (C64*)	<5
Other types of tumour	0

3. How many patients with Renal Cell Carcinoma (RCC) were treated with the following medicines, in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Name of monotherapy or combination	Number patients treated
3.1 Avelumab + Axitinib	<5

4. How many patients with Urothelial Carcinoma (UC) were treated with the following medicines, in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Name of monotherapy or combination	Number patients treated
4.1 Avelumab Monotherapy Maintenance	0
4.2 Atezolizumab	<5
4.3 Pembrolizumab Monotherapy	0
4.4 Pembrolizumab + Enfortumab vedotin	5
4.5 Nivolumab Monotherapy	<5
4.6 Nivolumab + Cisplatin + Gemcitabine	0
4.7 Durvalumab Monotherapy Maintenance	0
4.8 Durvalumab + Gemcitabine + Cisplatin	<5
4.9 Carboplatin+ Gemcitabine	<5
4.10 Paclitaxel Monotherapy	<5
4.11 Carboplatin + Paclitaxel	0
4.12 Cisplatin + Gemcitabine	6

11 June 2026

5. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Name of medicine	Number patients treated
5.1 Afibercept – (Zaltrap only)	0
5.2 Bevacizumab	71
5.3 Cetuximab	16
5.4 Encorafenib	32
5.5 Fruquintinib	<5
5.6 Nivolumab	102
5.7 Panitumumab	<5
5.8 Pembrolizumab	148
5.9 Regorafenib	<5
5.10 Trifluridine + Tipiracil (Lonsurf)	14

6. How many patients were treated for Colorectal Cancer (ICD-10 codes C18*, C19*, C20*, D010, D011, D012) with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Name of medicine	Number patients with CRC treated
6.1 Bevacizumab	26
6.2 Cetuximab	16
6.3 Encorafenib	<5
6.4 Nivolumab	0
6.5 Pembrolizumab	<5
6.6 Regorafenib	0
6.7 Trifluridine + Tipiracil (Lonsurf)	14

11 June 2026

7. How many patients were treated for Colorectal Cancer (ICD-10 codes C18*, C19*, C20*, D010, D011, D012) with the following combinations or chemotherapy and other agents in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Name of chemotherapy combination	Number patients with CRC treated
7.1 Bevacizumab + Trifluridine + Tipiracil	<5
7.2 Bevacizumab + FOLFOX	6
7.3 Bevacizumab + FOLFIRI	5
7.4 Cetuximab + FOLFIRI	13
7.5 Cetuximab + FOLFOX	0
7.6 Cetuximab + FOLFIRINOX / FOLFOXIRI	0
7.7 Cetuximab Monotherapy	0
7.8 Panitumumab + FOLFIRI	0
7.9 Panitumumab + FOLFOX	<5
7.10 Panitumumab + FOLFIRINOX / FOLFOXIRI	0
7.11 Capecitabine + Oxaliplatin (XELOX)	19
7.12 Capecitabine + Irinotecan (XELIRI)	<5

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.